<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342314</url>
  </required_header>
  <id_info>
    <org_study_id>15503</org_study_id>
    <secondary_id>I7U-MC-GAHA</secondary_id>
    <nct_id>NCT02342314</nct_id>
  </id_info>
  <brief_title>A Study of LY3143753 and LY3185643 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3143753 and LY3185643 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves a single dose of LY3143753 or LY3185643, given as an injection into the
      abdomen. The study will evaluate the effects of the LY3143753 or LY3185643 on your body. The
      study is approximately 12 weeks for each participant, not including screening. Screening is
      required within 28 days prior to the start of the study. This study involves Part A
      (LY3143753) and Part B (LY3185643). Participants may only enroll in one part and at one dose
      level.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (estimated as 84 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3143753 and LY3185643</measure>
    <time_frame>Predose up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) versus Time Curve of LY3143753 and LY3185643</measure>
    <time_frame>Predose up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of LY3143753 and LY3185643</measure>
    <time_frame>Predose up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD): Absolute Maximum Blood Glucose of LY3143753 and LY3185643</measure>
    <time_frame>Predose up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD): Maximum Glucose Increase of LY3143753 and LY3185643</measure>
    <time_frame>Predose up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD): Time to Maximum Blood Glucose of LY3143753 and LY3185643</measure>
    <time_frame>Predose up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc Change from Baseline to 8 Hours Post Drug Administration</measure>
    <time_frame>Baseline, 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3143753 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3185643 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC injection of ascending doses of LY3185643 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single SC injection of normal saline on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3143753 (Part A)</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>LY3143753 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3185643 (Part B)</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>LY3185643 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

        Exclusion Criteria:

          -  Are investigator site personnel directly affiliated with this study and their
             immediate families

          -  Are currently enrolled in a clinical trial involving an investigational product (IP)
             or off-label use of a drug or device

          -  Have participated, within the last 3 months, in a clinical trial

          -  Have known or ongoing psychiatric disorders

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  History of/current phaeochromocytoma

          -  History of/current insulinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>February 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

